Research Analysts Set Expectations for Actinium Pharmaceuticals, Inc.’s FY2024 Earnings (NYSEAMERICAN:ATNM)

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) – Investment analysts at Cantor Fitzgerald upped their FY2024 earnings per share (EPS) estimates for Actinium Pharmaceuticals in a research note issued to investors on Tuesday, April 30th. Cantor Fitzgerald analyst K. Kluska now forecasts that the biotechnology company will post earnings per share of ($1.35) for the year, up from their prior estimate of ($1.84). Cantor Fitzgerald currently has a “Overweight” rating and a $21.00 price objective on the stock. The consensus estimate for Actinium Pharmaceuticals’ current full-year earnings is ($1.59) per share.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last issued its quarterly earnings data on Friday, March 29th. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.21. The company had revenue of $0.08 million for the quarter.

A number of other research analysts have also recently issued reports on ATNM. Maxim Group lifted their price objective on Actinium Pharmaceuticals from $20.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, March 19th. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price target on shares of Actinium Pharmaceuticals in a report on Monday, April 29th. Finally, StockNews.com raised Actinium Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, April 29th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, Actinium Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $25.72.

Actinium Pharmaceuticals Price Performance

Shares of NYSEAMERICAN ATNM opened at $8.91 on Thursday. The firm has a market cap of $265.34 million, a price-to-earnings ratio of -5.21 and a beta of 0.08. Actinium Pharmaceuticals has a 52-week low of $4.00 and a 52-week high of $9.86.

Institutional Trading of Actinium Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Brandywine Global Investment Management LLC bought a new position in shares of Actinium Pharmaceuticals in the 3rd quarter worth $1,033,000. Creative Financial Designs Inc. ADV lifted its stake in Actinium Pharmaceuticals by 19.1% in the fourth quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock valued at $101,000 after buying an additional 3,175 shares during the period. Finally, Sanders Morris Harris LLC acquired a new position in Actinium Pharmaceuticals in the first quarter valued at about $78,000. 27.50% of the stock is currently owned by institutional investors and hedge funds.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.